Evaluating biomarkers for diagnosing minimal hepatic encephalopathy in cirrhotic patients

The performance of neurodegenerative biomarkers-neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1)-in diagnosing minimal hepatic encephalopathy (MHE) has not been systematically evaluated, simultaneously, nor have their associations with the development of overt hepatic encephalopathy (OHE).

Antonin (Tony) de Fougerolles appointed as new Chair of etherna

etherna, a leading mRNA technologies company, today announced the appointment of Antonin (Tony) de Fougerolles as Chair. Tony has served as an Independent Board Member

July 10, 2024

Researchers produce artificial cells with potential for drug delivery and tissue engineering

Artificial cells, made with the use of synthetic materials, have been produced in international research led at the University of Strathclyde.

December 11, 2023

J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition – Pharmaceutical Technology

NM26 is designed to inhibit the interleukin (IL)-4R and IL-31 cytokine pathways. Credits: Michael Vi/Shutterstock.com Johnson & Johnson (J&J) has announced that it has completed

July 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.